A RCT With Factorial Design to Compare Safety and Efficacy of 2 Capsules of the Indian Polycap Versus a Single Capsule Along With or Without Oral Potassium Among Patients With Stable Cardiovascular Disease
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 518
- 主要终点
- Tolerability of a Double Dose of Half Strength Polycap
研究概览
简要总结
This is a randomized double blind 2x2 factorial controlled trial to evaluate efficacy tolerability of low strength Polycap versus two doses of low strength Polycap in patients with stable cardiovascular disease in reducing blood pressure and LDL.
To evaluate the tolerability and safety of low dose potassium supplementation compared to placebo in patients with stable cardiovascular disease.
Approximately 500 patients are planned to be randomized.
详细描述
Mean change in blood pressure between those taking 2capsules of the polycap versus one Difference in Rates of early discontinuation between 2 capsules of polycap versus one Rates of reported adverse effects among those taking the polycap
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 40 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Individuals 40 years and above, with a seated blood pressure > 130/80 mm Hg on two consecutive readings (or BP > 120/80 mm Hg in patients under treatment with 2 or more antihypertensive medication) with one of the following
- •Coronary artery disease; previous myocardial infarction (>7 days post uncomplicated MI), or
- •Ischemic heart disease with significant ECG changes or a positive stress test, or
- •Stable angina or unstable angina and with documented evidence of multi-vessel (angiography or ECG or CT angiography) coronary artery disease, or
- •PTCA or CABG Surgery >30 days before informed consent.
- •Cerebrovascular disease; Previous Ischemic stroke or Transient Ischemic Attacks >30 days before informed consent.
- •High risk diabetes mellitus defined as HbA1C >7.5%, with microalbuminuria or blood pressure >140/90 mm Hg.
- •Peripheral artery disease defined as a current or prior history of: physician diagnosed intermittent claudication or vascular surgery for atherosclerotic disease or an ankle/arm systolic blood pressure ratio ≤ 0.90 in either leg at rest, or angiographic or doppler study demonstrating ≥ 70% stenosis in a noncardiac artery.
- •Those who provide informed consent and can comply with medications and follow-up visits.
排除标准
- •Known hypersensitivity or intolerance to any of the study medications or a clear indication for full doses of beta blockers, RAAS blockers (ACEi, ARBs, Renin inhibitors, etc.), diuretics and statins.
- •History of bleeding or having hemorrhagic stroke anytime in the past or a need for continued anticoagulation therapy.
- •Patients having indication for higher doses of aspirin or needing more than 75mg of clopidogrel daily.
- •Have significant bradycardia (heart rate <50 beats/min) or second- or third-degree heart block without a pacemaker.
- •Planned cardiac surgery or PTCA or any non-cardiac surgery <3months of eligibility assessment.
- •Heart transplant recipient.
- •Renal dysfunction defined as serum creatinine >2 mg/dL and/or serum potassium >5.0 mEq/L.
- •Patients aged >70 years, with mild renal dysfunction defined as serum creatinine >124 µmol/L (1.4 mg/dL) or eGFR <45 ml/min/1.73 m
- •Hepatic dysfunction, SGOT or SGPT > 3 x ULN.
- •Taking another experimental drug or within 30days of last dose of the experimental drug.
- •Peptic ulcer disease with bleed, or bleeding diathesis.
- •Bronchial asthma or Chronic Obstructive Pulmonary Disease with asthma.
- •Gout, rheumatoid arthritis or other chronic inflammatory disease requiring long-term medications with NSAIDs.
- •Any history of muscular pain, other pathology of the muscles or past history of muscular pain secondary to taking statins or fibrates.
- •Pregnancy or lactating or women of childbearing potential with inadequate contraception.
- •Inability to attend follow up visits (due to significant disability, inadequate address or contact details, subject from a far off place, psychiatric illness etc.).
研究组 & 干预措施
SD Polycap without potassium
Single dose polycap without pottasium
干预措施: Single Dose Polycap (Drug)
DD Polycap plus potassium
Double Dose polycap with potassium
干预措施: Double dose Polycap (Drug)
结局指标
主要结局
Tolerability of a Double Dose of Half Strength Polycap
时间窗: 8 weeks
BLOOD PRESSURE LIPIDS
时间窗: 8 weeks
Amongst patients with cardiovascular disease or type 2 diabetes, the study aims to test the safety and efficacy of giving double dose of polycap versus a single dose of polycap for 8 weeks; efficacy to lower blood pressure and elevated lipids and safety assessed as difference with tolerance to double dose of polycap compared to a single dose.
次要结局
- Blood Pressure Reduction and Lipid Lowering in Type 2 Diabetics(8 weeks)